120 related articles for article (PubMed ID: 28676324)
1. 24-Norursodeoxycholic acid in patients with primary sclerosing cholangitis: A new "urso saga" on the horizon?
Chazouillères O
J Hepatol; 2017 Sep; 67(3):446-447. PubMed ID: 28676324
[No Abstract] [Full Text] [Related]
2. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
3. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
[TBL] [Abstract][Full Text] [Related]
4. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Wagner M; Marschall HU; Fuchsbichler A; Zollner G; Tsybrovskyy O; Zatloukal K; Liu J; Waalkes MP; Cover C; Denk H; Hofmann AF; Jaeschke H; Trauner M
Gastroenterology; 2006 Feb; 130(2):465-81. PubMed ID: 16472600
[TBL] [Abstract][Full Text] [Related]
5. Therapy of Primary Sclerosing Cholangitis--Today and Tomorrow.
Halilbasic E; Fuchs C; Hofer H; Paumgartner G; Trauner M
Dig Dis; 2015; 33 Suppl 2():149-63. PubMed ID: 26641242
[TBL] [Abstract][Full Text] [Related]
6. 24-Norursodeoxycholic acid reshapes immunometabolism in CD8
Zhu C; Boucheron N; Müller AC; Májek P; Claudel T; Halilbasic E; Baazim H; Lercher A; Viczenczova C; Hainberger D; Preglej T; Sandner L; Alteneder M; Gülich AF; Khan M; Hamminger P; Remetic J; Ohradanova-Repic A; Schatzlmaier P; Donner C; Fuchs CD; Stojakovic T; Scharnagl H; Sakaguchi S; Weichhart T; Bergthaler A; Stockinger H; Ellmeier W; Trauner M
J Hepatol; 2021 Nov; 75(5):1164-1176. PubMed ID: 34242699
[TBL] [Abstract][Full Text] [Related]
7. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.
Halilbasic E; Fiorotto R; Fickert P; Marschall HU; Moustafa T; Spirli C; Fuchsbichler A; Gumhold J; Silbert D; Zatloukal K; Langner C; Maitra U; Denk H; Hofmann AF; Strazzabosco M; Trauner M
Hepatology; 2009 Jun; 49(6):1972-81. PubMed ID: 19475687
[TBL] [Abstract][Full Text] [Related]
8. Characterization of ursodeoxycholic and norursodeoxycholic acid as substrates of the hepatic uptake transporters OATP1B1, OATP1B3, OATP2B1 and NTCP.
König J; Klatt S; Dilger K; Fromm MF
Basic Clin Pharmacol Toxicol; 2012 Aug; 111(2):81-6. PubMed ID: 22333292
[TBL] [Abstract][Full Text] [Related]
9. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
Stiehl A; Rudolph G; Sauer P; Theilmann L
J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
[TBL] [Abstract][Full Text] [Related]
10. Macrophages in cholangiopathies.
Bruneau A; Guillot A; Tacke F
Curr Opin Gastroenterol; 2022 Mar; 38(2):114-120. PubMed ID: 35098932
[TBL] [Abstract][Full Text] [Related]
11. Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases.
Halilbasic E; Steinacher D; Trauner M
Dig Dis; 2017; 35(3):288-292. PubMed ID: 28249255
[TBL] [Abstract][Full Text] [Related]
12. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.
Assis DN; Abdelghany O; Cai SY; Gossard AA; Eaton JE; Keach JC; Deng Y; Setchell KD; Ciarleglio M; Lindor KD; Boyer JL
J Clin Gastroenterol; 2017 Feb; 51(2):e11-e16. PubMed ID: 27428727
[TBL] [Abstract][Full Text] [Related]
13. [Primary sclerosing cholangitis with itching treated during pregnancy with ursodeoxycholic acid].
Christensen KL; Andersen BN; Vilstrup H
Ugeskr Laeger; 1997 Nov; 159(48):7151-3. PubMed ID: 9417723
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM; Schrumpf E
Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies.
Trauner M; Halilbasic E; Kazemi-Shirazi L; Kienbacher C; Staufer K; Traussnigg S; Hofer H
Dig Dis; 2014; 32(5):631-6. PubMed ID: 25034298
[TBL] [Abstract][Full Text] [Related]
16. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.
Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
Hepatology; 2004 Sep; 40(3):693-8. PubMed ID: 15349909
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.
Fickert P; Pollheimer MJ; Silbert D; Moustafa T; Halilbasic E; Krones E; Durchschein F; Thüringer A; Zollner G; Denk H; Trauner M
J Hepatol; 2013 Jun; 58(6):1201-8. PubMed ID: 23369794
[TBL] [Abstract][Full Text] [Related]
19. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
Rust C; Beuers U
Clin Rev Allergy Immunol; 2005 Apr; 28(2):135-45. PubMed ID: 15879619
[TBL] [Abstract][Full Text] [Related]
20. NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice.
Krones E; Eller K; Pollheimer MJ; Racedo S; Kirsch AH; Frauscher B; Wahlström A; Ståhlman M; Trauner M; Grahammer F; Huber TB; Wagner K; Rosenkranz AR; Marschall HU; Fickert P
J Hepatol; 2017 Jul; 67(1):110-119. PubMed ID: 28242240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
